Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crocin and risperidone for withdrawal-related pain and anxiety
IRCT20200721048159N9Phase 3Completed
- Sponsor
- Lorestan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetaminophen and risperidone in substance withdrawal, opioid use disorder (OUD) and stimulant use disorder (SUD) (4 arms), sponsored by Lorestan University of Medical Sciences. Primary endpoints: Anxiety from addiction withdrawal and Pain from addiction withdrawal. Started Jan 2025; status: completed.
02
Drugs
acetaminophenrisperidone
03
Conditions
substance withdrawalopioid use disorder (OUD)stimulant use disorder (SUD)
Beyond the preview
Go deeper on IRCT20200721048159N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200721048159N9.